Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |
Not provided
Not provided
Not provided
Drug-drug interaction study of midazolam and AT-527 (R07496998)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AT-527 550 mg + midazolam (simultaneous) | Experimental | n=12 |
|
| AT-527 mg + midazolam (staggered) | Experimental | n=12 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AT-527 550 mg + midazolam | Drug | Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening. Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening. Other Names: AT-527 is also know as R07496998 |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK) of midazolam | Maximum plasma concentration (Cmax) and Area under the concentration-time curve (AUC) | Day 1, Day 3, Day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK) of AT-527 | Maximum plasma concentration (Cmax) and Area under the concentration-time curve (AUC) | Day 3, Day 7 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Atea Study Site | Montreal | Montreal, Quebec | Canada |
Not provided
| ID | Term |
|---|---|
| C000713067 | AT-511 |
| D008874 | Midazolam |
| ID | Term |
|---|---|
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| AT-527 550 mg + midazolam | Drug | Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening. Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening. Other Names: AT-527 is also know as R07496998 |
|
| D006571 | Heterocyclic Compounds |